Peripheral Arterial Disease | Treatment Algorithms: Claims Data Analysis | US | 2019
Peripheral arterial disease (PAD) is a complex manifestation of underlying atherosclerotic disease and is closely associated with coronary and cerebrovascular disease. Current treatment practice largely focuses on both lifestyle modifications and the use of statins, antihypertensives, and antiplatelet agents as cornerstone therapies to prevent events such as MI and stroke in these patients. The emergence of PCSK9 inhibitors to achieve aggressive LDL cholesterol lowering on top of statins is another therapeutic option for PAD patients.
QUESTIONS ANSWERED
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed PAD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PAD patients?
- What percentage of PAD patients receive drug therapy within six months of diagnosis, and how quickly do they receive it?
- What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of PAD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients with PAD?
Related Market Assessment Reports
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. Symptoms range from general malaise to serious renal and CNS manifestations…
Report
Chronic Kidney Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Kidney Disease (US)
Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises therapies, which are…
Report
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche…
